Total cholesterol

There are 2,864 papers on total cholesterol in aging research: 738 trials and 1,437 observational studies in people, 205 in animals, 5 in cells, 436 reviews.

Biomarker

2,864 papers study it435 more mention it786 findings

242 new papers in 30 daysSee all 3,299 papers on total cholesterol

At a glance

A human genetic study links higher total cholesterol with higher vascular dementia risk in people of European ancestry. Human trials report lower total cholesterol with whole grains and exercise, higher levels with low-carbohydrate or ketogenic diets, and no clear effect with some other interventions.

786 findings in 683 papers from 1989 to 2026, 127 of them since April 2026

“Some increases in triglycerides, total cholesterol, low-density lipoprotein and a decrease in high-density lipoproteins were observed in all analyzed groups.”
Does Alcohol Withdrawal Influence Arterial Stiffness and Classical Risk Factors for Cardiovascular Disease for Persons With Alcohol Use Disorder?Alcohol and alcoholism (Oxford, Oxfordshire)2022doi:10.1093/alcalc/agac069
  • Human trial738
  • Humans1,437
  • Animals204
  • Model organisms1
  • Cells5
  • In silico17

Interventions

273

Resveratrol

downin humans11no changein humans6upin humans5downin mice1+1

24 studies
  1. Resveratrol increases total cholesterol in humans (RSV: 9.88 mg/dL vs. ER: −13.54 mg/dL).

    “Furthermore, differences between the mean changes of serum total cholesterol (RSV: 9.88 mg/dL vs. ER: −13.54 mg/dL; p < 0.001), LDL-c (RSV: 7.21 mg/dL vs. ER: −8.38 mg/dL; p = 0.006), triglycerides (RSV: 24.58 mg/dL vs. ER: −9.21 mg/dL; p = 0.048), apoB (RSV: 0.06 g/L vs. ER: −0.06 g/L; p = 0.004), and glucose (RSV: 2.54 mg/dL vs. ER: −3.08 mg/dL; p = 0.033) were observed among the RSV and ER groups”

    Human trial30-daysn = 48

    Comparison of Resveratrol Supplementation and Energy Restriction Effects on Sympathetic Nervous System Activity and Vascular Reactivity: A Randomized Clinical Trial

    Molecules (Basel, Switzerland)

  2. Resveratrol decreases total cholesterol in humans (new diagnosis of dyslipidemia) (201.4 ± 34.4 versus 220.6 ± 37.4, P = 0.04).

    “individuals in the resveratrol group showed a significant decrease in total cholesterol (201.4 ± 34.4 versus 220.6 ± 37.4, P = 0.04) and triacylglycerol”

    Human trialnew diagnosis of dyslipidemia100 mg/d2 mon = 71

    Effect of resveratrol supplementation on lipid profile in subjects with dyslipidemia: A randomized double-blind, placebo-controlled trial

    Nutrition (Burbank, Los Angeles County, Calif.)

  3. Resveratrol increases total cholesterol in humans (type 2 diabetes mellitus).

    “Total cholesterol and triglycerides slightly increased in the Resv500arm.”

    Human trialtype 2 diabetes mellitus500mg/day6 monthsn = 192

    Six months of resveratrol supplementation has no measurable effect in type 2 diabetic patients. A randomized, double blind, placebo-controlled trial

    Pharmacological research

  4. Resveratrol increases total cholesterol in humans.

    “small but statistically significant increases in liver enzymes, total cholesterol, and triglycerides were observed”

    Human trial4-weekn = 13

    Effect of resveratrol on exercise capacity: a randomized placebo-controlled crossover pilot study

    Applied physiology, nutrition, and metabolism = Physiologie appliquee, nutrition et metabolisme

  5. Resveratrol decreases total cholesterol in patients with type 2 diabetes mellitus receiving oral hypoglycemic agents (4.70 ± 0.90 vs 4.33 ± 0.76, P < .05).

    “total cholesterol (mean ± SD, 4.70 ± 0.90 vs 4.33 ± 0.76; P < .05)”

    Human trialin patients with type 2 diabetes mellitus receiving oral hypoglycemic agents250 mg/d3 monthsn = 62

    Resveratrol supplementation improves glycemic control in type 2 diabetes mellitus

    Nutrition research (New York, N.Y.)

  6. Resveratrol decreases total cholesterol in humans (overweight adults) (MD = -0.19 mmol/L, 95% CI = -0.32, -0.06).

    “total cholesterol among overweight adults (MD = -0.19 mmol/L, 95% CI = -0.32, -0.06)”

    Reviewoverweight adults

    Effects of resveratrol supplementation on multiple health outcomes: an umbrella review of systematic reviews and meta-analyses of randomized controlled trials

    Nutrition journal

  7. Resveratrol decreases total cholesterol in humans (obesity-related metabolic disorders or associated risk factors).

    “Resveratrol significantly reduced the homeostatic model assessment of insulin resistance (HOMA-IR), total cholesterol (TC)”

    Reviewobesity-related metabolic disorders or associated risk factors

    Resveratrol Supplementation and its Potential Benefits in Obesity-related Non-communicable Diseases

    In vivo (Athens, Greece)

  8. Resveratrol showed no clear effect on total cholesterol in randomized controlled trials.

    “showed no significant effects on total cholesterol, low-density lipoprotein, or high-density lipoprotein”

    Reviewin randomized controlled trialsn = 337

    Anti-inflammatory mechanism of resveratrol's Triglyceride-lowering effect in hyperlipidemia: a meta-analysis integrated network pharmacology and molecular dynamics simulation

    Clinical and experimental medicine

  9. Resveratrol showed no clear effect on total cholesterol in humans (postmenopausal women) (SMD -0.09 (95% CI -0.39 to 0.22)).

    “The meta-analysis on total cholesterol levels found no significant difference between groups”

    Reviewpostmenopausal womenfemales

    Effects of resveratrol on the lipid profile of post-menopause women: Systematic review and meta-analysis

    Nutrition, metabolism, and cardiovascular diseases : NMCD

  10. Resveratrol decreases total cholesterol in humans (SMD = -0.20, 95 % CI: -0.31, -0.08; p= 0.001).

    “total cholesterol (TC) (SMD = -0.20, 95 % CI: -0.31, -0.08; p= 0.001)”

    Review

    Efficacy of resveratrol supplementation on lipid profile parameters: An umbrella of meta-analysis

    Prostaglandins & other lipid mediators

All 24

More on Resveratrol

Berberine

downin humans11downin hamsters1no changein humans1

13 studies
  1. Berberine decreases total cholesterol in humans (MAFLD) (p=0.0009).

    “a significant divergence between the BBR and placebo groups was evident in the alteration of Δ total cholesterol (TC) p=0.0009, favoring the BBR group”

    Human trialMAFLDoral1500 mg/day12 weeksn = 70

    Does berberine impact anthropometric, hepatic, and metabolic parameters in patients with metabolic dysfunction-associated fatty liver disease? Randomized, double-blind placebo-controlled trial

    Journal of physiology and pharmacology : an official journal of the Polish Physiological Society

  2. Berberine decreases total cholesterol in overweight subjects with impaired fasting blood glucose, versus placebo (β=-0.25 (95% CI -0.45; -0.04), p=0.05).

    “total cholesterol [β=-0.25, 95% C.I. (-0.45; -0.04), p=0.05]”

    Human trialin overweight subjects with impaired fasting blood glucose, versus placebophytosome (phospholipid complex)2 tablets/day, 550 mg/tablettwo monthsn = 49

    Berberine phospholipid exerts a positive effect on the glycemic profile of overweight subjects with impaired fasting blood glucose (IFG): a randomized double-blind placebo-controlled clinical trial

    European review for medical and pharmacological sciences

  3. Berberine decreases total cholesterol in humans (schizophrenia spectrum disorders with metabolic syndrome) (MD -0.58, 95% CI -0.74 to -0.41, P < 0.001, d = 1.31).

    “Patients who received berberine also showed statistically significant improvements in end point in body mass index (MD, -0.41; 95% CI, -0.65 to -0.17 [P = 0.001, d = 0.64]), total cholesterol (MD, -0.58; 95% CI, -0.74 to -0.41 [P < 0.001, d = 1.31]), low-density lipoprotein (MD, -0.52; 95% CI, -0.68 to -0.35 [P < 0.001, d = 1.19]), and glycated hemoglobin (MD, -0.09; 95% CI, -0.18 to 0 [P = 0.05, d = 0.37]).”

    Human trialschizophrenia spectrum disorders with metabolic syndrome600 mg/d12 weeksn = 113

    Adjunctive berberine reduces antipsychotic-associated weight gain and metabolic syndrome in patients with schizophrenia: a randomized controlled trial

    Psychiatry and clinical neurosciences

  4. Berberine decreases total cholesterol in humans.

    “After 12 weeks of intervention, men taking berberine had a larger reduction in total cholesterol and HDL-c than those taking placebo.”

    Human trial12 weeksmalesn = 84

    Effect of Berberine on Cardiovascular Disease Risk Factors: A Mechanistic Randomized Controlled Trial

    Nutrients

  5. Berberine decreases total cholesterol in humans (-0.39 mmol/L, 95% CI -0.70 to -0.08).

    “Men randomized to berberine had larger reductions in total cholesterol (-0.39 mmol/L, 95% confidence interval (CI) -0.70 to -0.08) and high-density lipoprotein cholesterol (-0.07 mmol/L, 95% CI -0.13 to -0.01) after 12 weeks.”

    Human trial500 mg orally, twice a day12 weeksmalesn = 80

    Effect of Berberine on Cardiovascular Disease Risk Factors: A Mechanistic Randomized Controlled Trial

    Nutrients

  6. Berberine decreases total cholesterol in humans (adjunctive treatment) (all p<0.05).

    “Berberine led to significant declines in total cholesterol, low-density lipoprotein cholesterol, fasting serum insulin, and insulin resistance(all p<0.05) compared with placebo.”

    Human trialadjunctive treatment900mg/day8 weeksn = 49

    The effect of berberine adjunctive treatment on glycolipid metabolism in patients with schizophrenia: A randomized, double-blind, placebo-controlled clinical trial

    Psychiatry research

  7. Berberine decreases total cholesterol in humans (mixed dyslipidemia).

    “BBR reduced TC levels.”

    Human trialmixed dyslipidemiaoral500 mg t.i.d.90 daysn = 12

    Effect of Berberine Plus Bezafibrate Administration on the Lipid Profile of Patients with Mixed Dyslipidemia: A Pilot Clinical Trial

    Journal of medicinal food

  8. Berberine decreases total cholesterol in humans (mild hyperlipidemia).

    “TG, TC, and LDL-C all decreased, and HDL-C increased in the treatment group (all P < 0.05).”

    Human trialmild hyperlipidemia300 mg thrice per day3 successive months

    Therapeutic Effects of Berberine Capsule on Patients with Mild Hyperlipidemia

    Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine

  9. Berberine decreases total cholesterol in humans (new diagnosed type 2 diabetes combining nonalcoholic fatty liver disease).

    “ALT, AST, TC, TG, LDL-L, hemorrheology (including the whole blood viscosity, whole blood viscosity, high cutting reduction of whole blood viscosity, plasma cutting reductive low viscosity, blood sedimentation, RBC deposited, fibrinogen) were significantly lower than before”

    Human trialnew diagnosed type 2 diabetes combining nonalcoholic fatty liver disease12 weeks

    Research on therapeutic effect and hemorrheology change of berberine in new diagnosed patients with type 2 diabetes combining nonalcoholic fatty liver disease

    Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica

  10. Berberine showed no clear effect on total cholesterol in humans (compared to routine or statins) (SMD 0.43, 95% CI -0.39 to 1.24).

    “There were no differences between berberine alone and routine or statins in improving total cholesterol (TC) (SMD, 0.43; 95% CI, -0.39 to 1.24; p = 0.30; I2 = 95%)”

    Reviewcompared to routine or statins

    Efficacy and safety of berberine for several cardiovascular diseases: A systematic review and meta-analysis of randomized controlled trials

    Phytomedicine : international journal of phytotherapy and phytopharmacology

All 14

More on Berberine

Testosterone

downin humans12

12 studies
  1. Testosterone decreases total cholesterol in humans (compared with placebo gel in older men with low testosterone) (-6.1 mg/dL adjusted mean difference; P < 0.001).

    “testosterone treatment significantly decreased total cholesterol (adjusted mean difference, -6.1 mg/dL; P < 0.001)”

    Human trialcompared with placebo gel in older men with low testosteronegeladjusted to maintain the testosterone level in the normal range for young men12 monthsmales

    The Effect of Testosterone on Cardiovascular Biomarkers in the Testosterone Trials

    The Journal of clinical endocrinology and metabolism

  2. Testosterone decreases total cholesterol in humans (low-normal testosterone levels).

    “Total cholesterol and HDL cholesterol decreased in the testosterone group”

    Human triallow-normal testosterone levelstestosterone undecenoate80 mg twice daily6 monthsmales

    Does testosterone supplementation improve health and function in elderly men?

    Nature clinical practice. Endocrinology & metabolism

  3. Testosterone decreases total cholesterol in humans (hypogonadal men with type 2 diabetes) (-0.4 +/- 0.17 mmol/l, P = 0.03).

    “Total cholesterol decreased with testosterone therapy (-0.4 +/- 0.17 mmol/l, P = 0.03) but no effect on blood pressure was observed.”

    Human trialhypogonadal men with type 2 diabetesi.m.200 mg every 2 weeks3 monthsmales

    Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes

    European journal of endocrinology

  4. Testosterone decreases total cholesterol in hypogonadal men with ischaemic heart disease (-0.41 (0.54) mmol/l, p = 0.04).

    “testosterone therapy was also associated with a significant reduction of total cholesterol and serum tumour necrosis factor alpha with delta values of -0.41 (0.54) mmol/l”

    Human trialin hypogonadal men with ischaemic heart diseasea monthmalesn = 10

    Testosterone replacement in hypogonadal men with angina improves ischaemic threshold and quality of life

    Heart (British Cardiac Society)

  5. Testosterone decreases total cholesterol in humans (symptomatic androgen deficiency) (-0.25 +/- 0.4 vs. -0.004 +/- 0.4 mmol/liter, P = 0.04).

    “a significant reduction in total cholesterol was recorded with testosterone therapy (-0.25 +/- 0.4 vs. -0.004 +/- 0.4 mmol/liter; P = 0.04)”

    Human trialsymptomatic androgen deficiencySustanon 100serummalesn = 27

    The effect of testosterone replacement on endogenous inflammatory cytokines and lipid profiles in hypogonadal men

    The Journal of clinical endocrinology and metabolism

  6. Testosterone decreases total cholesterol in humans (testosterone deficiency).

    “We noticed significant decrease in total cholesterol, and LDL-cholesterol.”

    Human trialtestosterone deficiencytestosterone enanthate200 mg every second week1.5–6 yearsmalesn = 30

    The influence of testosterone replacement therapy on well-being, bone mineral density and lipids in elderly men

    Polskie Archiwum Medycyny Wewnetrznej

  7. Testosterone decreases total cholesterol in humans (Hypogonadism associated with aging or hypopituitarism) (Aging-associated hypogonadism: 225 ± 16.9 to 198 ± 12.8 mg/dl; hypopituitarism: 255 ± 12.1 to 206 ± 9 mg/dl at 1 year).

    “through decreasing total cholesterol and atherogenic fraction of LDL-cholesterol without significant alterations in HDL-cholesterol levels or its subfractions HDL2-C and HDL3-C.”

    Human trialHypogonadism associated with aging or hypopituitarismtestosterone enanthate200 mg every second week12 monthsmalesn = 22

    Effect of testosterone replacement therapy on lipids and lipoproteins in hypogonadal and elderly men

    Atherosclerosis

  8. Testosterone decreases total cholesterol in humans (WMD -10.20 mg/dL (95% CI -14.52, -5.88)).

    “TRT was associated with significant reductions in total cholesterol (WMD: -10.20; 95% CI: -14.52, -5.88 mg/dL; P = 0.005)”

    Reviewmales

    Cardiovascular safety in middle-aged and older men under testosterone replacement therapy: a systematic review and meta-analysis

    Endocrine

  9. Testosterone decreases total cholesterol in hypogonadal men with type 2 diabetes mellitus (WMD = -0.28 [-0.47, -0.09] p = 0.0008).

    “In addition, TST can decrease cholesterol (WMD = -0.28 [-0.47, -0.09] p = 0.0008; I2 = 91%)”

    Reviewin hypogonadal men with type 2 diabetes mellitusmalesn = 1,596

    Effects of testosterone therapy in adult males with hypogonadism and T2DM: A meta-analysis and systematic review

    Diabetes & metabolic syndrome

  10. Testosterone decreases total cholesterol in humans (late-onset hypogonadism) (MD = -0.433, 95% CI -0.761 to -0.105).

    “Among the lipid profiles, total cholesterol showed significant improvement (MD = - 0.433, 95% CI - 0.761, - 0.105) after TRT.”

    Reviewlate-onset hypogonadismmalesn = 1,373

    Efficacy of testosterone replacement therapy for treating metabolic disturbances in late-onset hypogonadism: a systematic review and meta-analysis

    International urology and nephrology

All 12

More on Testosterone

Vitamin D

downin humans7upin humans2no changein humans1

10 studies
  1. Vitamin D decreases total cholesterol in women with PCOS.

    “The BMI, WHR, insulin concentrations, homeostasis model assessment of insulin resistance (HOMA-IR), triglycerides (TG), total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-C) concentrations in women of Vitamin D group after 12 weeks of treatment were significantly lower than that in women of control group (P < 0.05).”

    Human trialin women with PCOS2000 IU/day12 weeksfemalesn = 60

    Effects of vitamin D supplementation on metabolic parameters in women with polycystic ovary syndrome: a randomized controlled trial

    Journal of ovarian research

  2. Vitamin D decreases total cholesterol in humans (subclinical hypothyroidism).

    “Vitamin D supplementation significantly decreased TSH, total cholesterol, and fat mass percentage”

    Human trialsubclinical hypothyroidismplasma-serum50,000 IU/week12 weeksfemalesn = 44

    Effects of vitamin D supplementation on metabolic parameters, serum irisin and obesity values in women with subclinical hypothyroidism: a double-blind randomized controlled trial

    Frontiers in endocrinology

  3. Vitamin D increases total cholesterol in humans (versus placebo in adults with arterial hypertension).

    “Vitamin D supplementation significantly increased total cholesterol, triglycerides, very-low-density lipoprotein (VLDL) triglycerides, low-density lipoprotein (LDL) triglycerides, high-density lipoprotein (HDL) triglycerides, apolipoprotein B (ApoB)”

    Human trialversus placebo in adults with arterial hypertension2800 IU daily8 weeksn = 163

    Vitamin D supplementation and lipoprotein metabolism: A randomized controlled trial

    Journal of clinical lipidology

  4. Vitamin D decreases total cholesterol in humans (polycystic ovary syndrome) (MD -11.69 mg/dL, 95% CI (-15.56, -7.82) mg/dL).

    “total cholesterol [MD=-11.69 mg/dL, 95% CI (-15.56, -7.82) mg/dL, P < 0.00001]”

    Reviewpolycystic ovary syndrome

    The impact of vitamin D supplementation on glycemic control and lipid metabolism in polycystic ovary syndrome: a systematic review of randomized controlled trials

    BMC endocrine disorders

  5. Vitamin D decreases total cholesterol in humans (SMD: - 0.14 mg/dl; 95% CI: - 0.25, - 0.02).

    “Results of random effect meta-analysis indicated a significant reduction in total cholesterol (TC) (SMD: - 0.14 mg/dl; 95% CI: - 0.25, - 0.02)”

    Review

    Effect of vitamin D supplementation on cardiac-metabolic risk factors in elderly: a systematic review and meta-analysis of clinical trials

    Diabetology & metabolic syndrome

  6. Vitamin D increases total cholesterol in humans (treatment duration <26 weeks) (WMD: 6.56 mg/dL, 95% CI: 0.78 to 12.35, P = 0.02).

    “vitamin D increased TC when the treatment duration was ˂26 weeks (WMD: 6.56 mg/dL, 95% CI: 0.78 to 12.35, P = 0.02)”

    Reviewtreatment duration <26 weeks<26 weeks

    The effect of vitamin D on the lipid profile as a risk factor for coronary heart disease in postmenopausal women: a meta-analysis and systematic review of randomized controlled trials

    Experimental gerontology

  7. Vitamin D decreases total cholesterol in humans (polycystic ovary syndrome) (SMD: -0.36 mg/dL, 95% CI: -0.54 to -0.18 mg/dL, P<0.0001).

    “reduction in total cholesterol (TC) concentrations (SMD: -0.36 mg/dL, 95% CI: -0.54 to -0.18 mg/dL, P<0.0001)”

    Reviewpolycystic ovary syndrome

    Effectiveness of vitamin D supplementation on lipid profile in polycystic ovary syndrome women: a meta-analysis of randomized controlled trials

    Annals of palliative medicine

  8. Vitamin D decreases total cholesterol in humans (polycystic ovary syndrome) (-9.09 mg/dL (95% CI: -14.90 to -3.29)).

    “total cholesterol (-9.09 mg/dL; 95% CI: -14.90 to -3.29)”

    Reviewpolycystic ovary syndromen = 467

    Influence of vitamin D supplementation on lipid levels in polycystic ovary syndrome patients: a meta-analysis of randomized controlled trials

    The Journal of international medical research

  9. Vitamin D decreases total cholesterol in humans (SMD -0.17 (-0.28 to -0.06)).

    “total cholesterol = -0.17 (-0.28 to -0.06)”

    Reviewserumn = 3,434

    Effect of vitamin D supplementation on serum lipid profiles: a systematic review and meta-analysis

    Nutrition reviews

  10. Vitamin D showed no clear effect on total cholesterol in humans (1.52 mg/dl (-1.42 to 4.46 mg/dl)).

    “No statistically significant effects for vitamin D supplementation were observed for TC, HDL-C and TG (differences in means were 1.52 mg/dl (-1.42 to 4.46 mg/dl)”

    Review

    Influence of vitamin D supplementation on plasma lipid profiles: a meta-analysis of randomized controlled trials

    Lipids in health and disease

More on Vitamin D

Curcumin

downin humans9no changein humans1

10 studies
  1. Curcumin decreases total cholesterol in humans (P = 0.015).

    “total cholesterol (P = 0.015), and triglyceride (P = 0.007) compared to placebo”

    Human trialcapsules500 milligram twice/dailyeight weeksfemales

    Curcumin and vitamin E improve hot flashes, lipid profile, and fasting blood glucose without any detrimental effect on the liver and renal function in postmenopausal women: A triple-blind placebo-controlled clinical trial

    Health care for women international

  2. Curcumin decreases total cholesterol in patients with diabetes on hemodialysis (β = -17.83 mg/dL, 95% CI: -29.22 to -6.45).

    “Nanocurcumin treatment was associated with a significant reduction in triglycerides (β = -16.13 mg/dL, 95% CI: -31.51 to -0.75; P < .05), VLDL-cholesterol (β = -3.22 mg/dL, 95% CI: -6.30 to -0.15; P < .05), total cholesterol (β = -17.83 mg/dL, 95% CI: -29.22 to -6.45; P < .05)”

    Human trialin patients with diabetes on hemodialysis80 mg/d12 weeksn = 60

    The Effects of Nano-curcumin on Metabolic Status in Patients With Diabetes on Hemodialysis, a Randomized, Double Blind, Placebo-controlled Trial

    Iranian journal of kidney diseases

  3. Curcumin decreases total cholesterol in humans (polycystic ovary syndrome) (β -15.86 mg/dL (95% CI, -24.48, -7.24)).

    “taking curcumin was associated with a significant reduction in total cholesterol (β -15.86 mg/dL; 95% CI, -24.48, -7.24; P = 0.001)”

    Human trialpolycystic ovary syndrome500 mg/day12 weeksfemalesn = 60

    Effects of curcumin on body weight, glycemic control and serum lipids in women with polycystic ovary syndrome: A randomized, double-blind, placebo-controlled trial

    Clinical nutrition ESPEN

  4. Curcumin decreases total cholesterol in humans (nonalcoholic fatty liver disease) (P < 0.001).

    “Supplementation with curcumin was associated with a reduction in serum levels of total cholesterol (P < 0.001)”

    Human trialnonalcoholic fatty liver disease1000 mg/d8 weeksn = 87

    Curcumin Lowers Serum Lipids and Uric Acid in Subjects With Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial

    Journal of cardiovascular pharmacology

  5. Curcumin decreases total cholesterol in humans (NAFLD) (WMD -11.81 (95% CI -19.65 to -3.96)).

    “was associated with significant reductions in levels of FBG, HOMA-IR, TG, TC, LDL, weight and BMI in patients with NAFLD.”

    ReviewNAFLD50–3000 mg/day8–12 weeksn = 1,191

    Curcumin effects on glycaemic indices, lipid profile, blood pressure, inflammatory markers and anthropometric measurements of non-alcoholic fatty liver disease patients: A systematic review and meta-analysis of randomized clinical trials

    Complementary therapies in medicine

  6. Curcumin decreases total cholesterol in humans (polycystic ovary syndrome) (WMD -15.591, 95% CI -27.908 to -3.273).

    “total cholesterol (WMD -15.591, 95% CI -27.908 to -3.273, P = 0.013, I2 = 68.9%)”

    Reviewpolycystic ovary syndrome

    Therapeutic effect and safety of curcumin in women with PCOS: A systematic review and meta-analysis

    Frontiers in endocrinology

  7. Curcumin decreases total cholesterol in humans (ES = -0.81 mg/dl, 95% CI: -1.39 to -0.24).

    “curcumin supplementation was effective on reduction of total cholesterol (TC) (ES = -0.81 mg/dl; 95% CI: 1.39, -0.24, p = 0.006”

    Review

    Curcumin as a novel approach in improving lipid profile: An umbrella meta-analysis

    Nutrition, metabolism, and cardiovascular diseases : NMCD

  8. Curcumin decreases total cholesterol in humans (polycystic ovary syndrome) (MD = -15.55, 95% CI [-30.33, -0.76], p < .04).

    “The mean difference in total cholesterol was also statistically significant (MD = -15.55; 95% CI = [-30.33, -0.76], p < .04).”

    Reviewpolycystic ovary syndromen = 296

    The effects of curcumin as dietary supplement for patients with polycystic ovary syndrome: An updated systematic review and meta-analysis of randomized clinical trials

    Phytotherapy research : PTR

  9. Curcumin decreases total cholesterol in humans (polycystic ovary syndrome) (MD -12.45, 95% CI -22.05 to -2.85).

    “It also significantly improves high-density lipoprotein (MD: 1.92, 95% CI: 0.33-3.51) and total cholesterol (MD: -12.45, 95% CI: -22.05 to -2.85).”

    Reviewpolycystic ovary syndrome

    Effects of Curcumin on Glycemic Control and Lipid Profile in Polycystic Ovary Syndrome: Systematic Review with Meta-Analysis and Trial Sequential Analysis

    Nutrients

  10. Curcumin showed no clear effect on total cholesterol in humans (8.97 (95% CI: -4.56 to 22.51) mg/dL, p = 0.19).

    “Meta-analysis of findings did not indicate a significant effect of curcumin on any of the lipid parameters.”

    Review

    A systematic review and meta-analysis of randomized controlled trials investigating the effects of curcumin on blood lipid levels

    Clinical nutrition (Edinburgh, Scotland)

More on Curcumin

Caloric restriction

downin humans5downin dogs1upin rats1downin reviews1+1

9 studies
  1. Caloric restriction decreases total cholesterol in humans (at 6% weight loss compared to baseline) (p = 0.04 and p = 0.008).

    “The total cholesterol, triglyceride and leptin concentrations were reduced at T2 compared to T0 (p = 0.04, p = 0.008 and p = 0.02, respectively).”

    Human trialat 6% weight loss compared to baseline

    Energetic adaptations in response to moderate calorie restriction-induced weight loss in normal-weight adults

    Physiology & behavior

  2. Caloric restriction decreases total cholesterol in humans (combined with FATmax exercise).

    “Subjects' serum TC decreased significantly”

    Human trialcombined with FATmax exercise4 weeks

    Optimal calorie restriction threshold: effect of FATmax exercise combined with different proportions of calorie restriction on hypercholesterolemia

    Frontiers in physiology

  3. Caloric restriction decreases total cholesterol in humans.

    “Adjustments for baseline values, compared with the control diet, the CRD dietary has resulted in significant reductions in TC (p = 0.028), but to a small size (ηp2 = 0.054).”

    Human trialdiet4 weeksn = 90

    Calorie-restricted diet mitigates weight gain and metabolic abnormalities in obese women with schizophrenia: a randomized controlled trial

    Frontiers in nutrition

  4. Caloric restriction decreases total cholesterol in humans (hospitalized obese women with schizophrenia) (-0.69 ± 0.70 mmol/L, p = 0.028).

    “as well as total cholesterol (0.69 ± 0.70 mmol/L) with a medium effect size (p = 0.028, ηp2 = 0.054).”

    Human trialhospitalized obese women with schizophrenia4 weeksfemales

    Calorie-restricted diet mitigates weight gain and metabolic abnormalities in obese women with schizophrenia: a randomized controlled trial

    Frontiers in nutrition

  5. Caloric restriction decreases total cholesterol in humans.

    “total cholesterol, LDL-cholesterol and IDL-cholesterol were significantly decreased by the calorie restriction”

    Human trialsix-monthfemalesn = 60

    Effect of dietary modification by calorie restriction on cholesterol levels in lipoprotein(a) and other lipoprotein classes

    Annals of clinical biochemistry

  6. Caloric restriction increases total cholesterol in overweight and obese rats.

    “it can significantly increase the blood concentration of TC in overweight and obese male rats.”

    Animalsin overweight and obese rats40% energy restrictionmales

    Impact of protein intake from a caloric-restricted diet on liver lipid metabolism in overweight and obese rats of different sexes

    Scientific reports

  7. Caloric restriction decreases total cholesterol in dogs (p < 0.0001).

    “significant reductions of serum total cholesterol, glucose, alkaline phosphatase, paraxonase-1 (all p < 0.0001) and gamma-glutamyltransferase (p < 0.018) were observed in both groups, regardless of supplementation.”

    Animals6 weeksn = 32

    Effect of a weight loss diet with or without Spirulina supplementation on serum lipids and antioxidant capacity of overweight dogs

    Scientific reports

  8. Caloric restriction decreases total cholesterol.

    “Fasting and caloric restriction have also been shown to beneficially influence gut microbiota composition, modify host metabolism, reduce total cholesterol and triglyceride levels”

    Review

    Effects of caloric restriction on immunosurveillance, microbiota and cancer cell phenotype: Possible implications for cancer treatment

    Seminars in cancer biology

  9. Caloric restriction decreases total cholesterol in humans.

    “Meta-analyses proved benefit of CR on reduction of body weight, BMI, fat mass, total cholesterol”

    Review

    Is Caloric Restriction Associated with Better Healthy Aging Outcomes? A Systematic Review and Meta-Analysis of Randomized Controlled Trials

    Nutrients

  10. Caloric restriction showed no clear effect on total cholesterol in rhesus monkeys.

    “had no effect on total serum cholesterol or blood pressure.”

    Animalsmalesn = 13

    Short-term calorie restriction improves disease-related markers in older male rhesus monkeys (Macaca mulatta)

    Mechanisms of ageing and development

More on Caloric restriction

Coenzyme Q10

downin humans7no changein humans2

9 studies
  1. Coenzyme Q10 decreases total cholesterol in humans (type 2 diabetes mellitus) (P=0.006).

    “total cholesterol (TC) (P=0.006), LDL-C (P=0.007) decreased and HDL-C (P=0.02) increased significantly in the drug group after intervention.”

    Human trialtype 2 diabetes mellitusserum100 mg/day12 weeksfemales

    Effects of Coenzyme Q10 Supplementation on Serum Values of Gamma-glutamyl transferase, Pseudocholinesterase, Bilirubin, Ferritin, and High-Sensitivity C-Reactive Protein in Women with Type 2 Diabetes

    Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association

  2. Coenzyme Q10 decreases total cholesterol in humans (type 2 diabetes) (P value=0.027).

    “Furthermore, mean differences of TC and LDL-C level were statistically altered between two groups (P value=0.027 and 0.039 respectively).”

    Human trialtype 2 diabetesdaily200 mg12 weeksn = 64

    The effect of coenzyme Q10 supplementation on metabolic status of type 2 diabetic patients

    Minerva gastroenterologica e dietologica

  3. Coenzyme Q10 decreases total cholesterol in humans (essential arterial hypertension) (from 222.9 +/- 13 mg/dl to 213.3 +/- 12 mg/dl).

    “Serum total cholesterol decreased from 222.9 +/- 13 mg/dl to 213.3 +/- 12 mg/dl (P < 0.005)”

    Human trialessential arterial hypertension50 mg twice daily10 weeksn = 26

    Coenzyme Q10 in essential hypertension

    Molecular aspects of medicine

  4. Coenzyme Q10 decreases total cholesterol in humans (metabolic disorders) (WMD = -4.86 mg/dL, 95% CI: -8.41, -1.30).

    “total cholesterol (TC, WMD = -4.86 mg/dL; 95% CI: -8.41, -1.30; p = 0.007)”

    Reviewmetabolic disorders

    Effects of Coenzyme Q10 on Lipid, Glycemic, and Inflammatory Markers in Metabolic Disorders: A Systematic Review and Meta-Analysis

    Journal of diabetes research

  5. Coenzyme Q10 decreases total cholesterol in humans (MD -5.53 mg/dL, 95% CI -8.40 to -2.66).

    “The pooled analysis revealed that CoQ10 supplementation significantly reduced total cholesterol (TC) (MD -5.53 mg/dL; 95% CI -8.40, -2.66; I2 = 70%)”

    Review

    Effects of Coenzyme Q10 Supplementation on Lipid Profiles in Adults: A Meta-analysis of Randomized Controlled Trials

    The Journal of clinical endocrinology and metabolism

  6. Coenzyme Q10 decreases total cholesterol in humans (coronary artery disease) (SMD -1.07; 95% CI, - 1.94, - 0.21, P = 0.01).

    “taking CoQ10 by patients with CAD significantly decreased total-cholesterol (SMD -1.07; 95% CI, - 1.94, - 0.21, P = 0.01)”

    Reviewcoronary artery disease

    The effects of coenzyme Q10 supplementation on lipid profiles among patients with coronary artery disease: a systematic review and meta-analysis of randomized controlled trials

    Lipids in health and disease

  7. Coenzyme Q10 showed no clear effect on total cholesterol in humans (patients with metabolic diseases) (SMD -0.07; 95% CI, -0.45, 0.31).

    “CoQ10 supplementation also decreased total-cholesterol (SMD -0.07; 95% CI, -0.45, 0.31)”

    Reviewpatients with metabolic diseases

    The Effects of Coenzyme Q10 Supplementation on Lipid Profiles Among Patients with Metabolic Diseases: A Systematic Review and Meta-analysis of Randomized Controlled Trials

    Current pharmaceutical design

  8. Coenzyme Q10 decreases total cholesterol in humans (patients diagnosed with CKD) (SMD -0.58, 95% CI -0.94 to -0.21).

    “CoQ10 supplementation significantly reduced total-cholesterol (SMD=-0.58; CI, -0.94, - 0.21; P=0.002; I2: 54.9)”

    Reviewpatients diagnosed with CKD

    The Effects of Coenzyme Q10 Supplementation on Metabolic Profiles of Patients with Chronic Kidney Disease: A Systematic Review and Meta-analysis of Randomized Controlled Trials

    Current pharmaceutical design

  9. Coenzyme Q10 showed no clear effect on total cholesterol in humans.

    “Neither total cholesterol and cholesterol subfractions, nor triglyceride levels were affected by CoQ10 supplementation.”

    Reviewn = 409

    Supplementation with coenzyme Q10 reduces plasma lipoprotein(a) concentrations but not other lipid indices: A systematic review and meta-analysis

    Pharmacological research

More on Coenzyme Q10

Dehydroepiandrosterone

downin humans7no changein humans1−11%

8 studies
  1. Dehydroepiandrosterone showed no clear effect on total cholesterol in schizophrenic patients treated with olanzapine.

    “There were no major changes in the overall cholesterol value, HDL cholesterol, LDL cholesterol or triglycerides in either group.”

    Human trialin schizophrenic patients treated with olanzapine100 mgtwelve-weekmalesn = 45

    The stabilizing effect of dehydroepiandrosterone on clinical parameters of metabolic syndrome in patients with schizophrenia treated with olanzapine - a randomized, double-blind trial

    Psychiatria polska

  2. Dehydroepiandrosterone decreases total cholesterol in humans (hypoadrenal) (20.0 vs. -22, P = 0.02).

    “DHEA replacement significantly reduced total cholesterol (20.0 vs. -22, P = 0.02)”

    Human trialhypoadrenaloralplasma50 mg/d3 monthsfemalesn = 33

    Effect of dehydroepiandrosterone replacement on lipoprotein profile in hypoadrenal women

    The Journal of clinical endocrinology and metabolism

  3. Dehydroepiandrosterone decreases total cholesterol in humans (hypoadrenal women) (P < 0.005).

    “DHEA also reduced total cholesterol (P < 0.005), triglycerides (P < 0.011), LDL cholesterol (P < 0.05), and HDL cholesterol (P < 0.005).”

    Human trialhypoadrenal women50-mg12 weeksfemalesn = 28

    Effect of dehydroepiandrosterone replacement on insulin sensitivity and lipids in hypoadrenal women

    Diabetes

  4. Dehydroepiandrosterone decreases total cholesterol in men with angiographically verified coronary heart disease, placebo-controlled crossover (222.9+/-6.6 to 207.4+/-6.6 mg/dL (p<0.05)).

    “Also total cholesterol levels and LDL-cholesterol levels decreased significantly (from 222.9+/-6.6 mg/dL to 207.4+/-6.6 mg/dL and from 143.9+/-6.9 mg/dL to 130.5+/-6.0 mg/dL respectively; p<0.05).”

    Human trialin men with angiographically verified coronary heart disease, placebo-controlled crossover150 mg daily40 daysmalesn = 30

    Positive effects of DHEA therapy on insulin resistance and lipids in men with angiographically verified coronary heart disease--preliminary study

    Endokrynologia Polska

  5. Dehydroepiandrosterone decreases total cholesterol in humans.

    “In vivo, DHEA increased flow-mediated dilation and laser Doppler velocimetry and reduced total plasma cholesterol.”

    Human trial3 monthsfemalesn = 36

    Dehydroepiandrosterone increases endothelial cell proliferation in vitro and improves endothelial function in vivo by mechanisms independent of androgen and estrogen receptors

    The Journal of clinical endocrinology and metabolism

  6. Dehydroepiandrosterone decreases total cholesterol in humans (Addison's disease).

    “only in patients with Addison's disease a significant decrease in total cholesterol and in low-density lipoproteins after 4 months of DHEA administration was found.”

    Human trialAddison's disease50 mg/day4 months

    Effects of dehydroepiandrosterone (DHEA) supplementation on hormonal, metabolic and behavioral status in patients with hypoadrenalism

    Journal of endocrinological investigation

  7. Dehydroepiandrosterone decreases total cholesterol in humans (-11.3%).

    “A marked decline of 11.3% (P less than 0.05) in serum cholesterol and 20.0% (P less than 0.05) in high density lipoprotein noted within the first week of DHEA administration”

    Human trialoral1600 mg/day28 daysfemalesn = 6

    The effects of oral dehydroepiandrosterone on endocrine-metabolic parameters in postmenopausal women

    The Journal of clinical endocrinology and metabolism

  8. Dehydroepiandrosterone decreases total cholesterol in humans (adrenal insufficiency).

    “In adrenal insufficiency, DHEA restores DHEA/DHEAS and androstenedione levels, reduces total cholesterol, improves well-being, sexual satisfaction and insulin sensitivity”

    Reviewadrenal insufficiency

    Dehydroepiandrosterone (DHEA): hypes and hopes

    Drugs

More on Dehydroepiandrosterone

Levocarnitine

downin humans6no changein humans2

7 studies
  1. Levocarnitine decreases total cholesterol in patients with chronic hepatitis C treated with interferon and ribavirin (total cholesterol 0.08 vs -0.91 mmol/l, triglycerides +0.25 vs -20 mmol/l).

    “total cholesterol 0.08 vs -0.91 mmol/l (P < 0.05) and triglycerides +0.25 vs -20 mmol/l (P < 0.05)”

    Human trialin patients with chronic hepatitis C treated with interferon and ribavirin2 g/day carnitine vs control12 monthsn = 70

    L-carnitine treatment reduces steatosis in patients with chronic hepatitis C treated with alpha-interferon and ribavirin

    Digestive diseases and sciences

  2. Levocarnitine decreases total cholesterol in humans (ES = -1.05 mg/dL, 95% CI: -1.71, -0.39).

    “L-carnitine supplementation significantly total cholesterol (TC) (ES = -1.05 mg/dL, 95% CI: -1.71, -0.39; p = 0.002)”

    Review> 2 g/day

    The effect of L-carnitine supplementation on lipid profile in adults: an umbrella meta-analysis on interventional meta-analyses

    Frontiers in nutrition

  3. Levocarnitine decreases total cholesterol in humans (MD = -6.45 mg dL−1, 95% CI: -9.95 to -2.95).

    “TG (MD = -11.22 mg dL−1, 95% CI: -19.21 to -3.22), TC (MD = -6.45 mg dL−1, 95% CI: -9.95 to -2.95, LDLc (MD = -8.28 mg dL−1, 95% CI: -11.08 to -5.47)”

    Review

    Effects of L-carnitine supplementation on glucolipid metabolism: a systematic review and meta-analysis

    Food & function

  4. Levocarnitine decreases total cholesterol in humans (type 2 diabetes) (WMD -8.17 mg/dL, 95% CI -14.68 to -1.65).

    “L-carnitine supplementation significantly reduced total cholesterol (TC) (weighted mean difference [WMD]: -8.17 mg/dL; 95% CI,-14.68 to -1.65, I2=52.2%, P = 0.041).”

    Reviewtype 2 diabetes

    The effects of L-carnitine supplementation on lipid concentrations inpatients with type 2 diabetes: A systematic review and meta-analysis of randomized clinical trials

    Journal of cardiovascular and thoracic research

  5. Levocarnitine showed no clear effect on total cholesterol in patients under hemodialysis treatment.

    “Subgroup analyses showed that l-carnitine supplementation did not change TC, LDL-C and TG in patients under hemodialysis treatment.”

    Reviewin patients under hemodialysis treatment

    Efficacy of l-carnitine supplementation for management of blood lipids: A systematic review and dose-response meta-analysis of randomized controlled trials

    Nutrition, metabolism, and cardiovascular diseases : NMCD

  6. Levocarnitine decreases total cholesterol in humans (MD: -8.53 mg/dl, 95% CI: -13.46, -3.6).

    “meta-analysis revealed that l-carnitine supplementation significantly reduced total cholesterol (TC) (56 arms-MD: -8.53 mg/dl, 95% CI: -13.46, -3.6, I2: 93%)”

    Reviewsupplementation

    Efficacy of l-carnitine supplementation for management of blood lipids: A systematic review and dose-response meta-analysis of randomized controlled trials

    Nutrition, metabolism, and cardiovascular diseases : NMCD

  7. Levocarnitine decreases total cholesterol in humans (WMD: -9.47, 95% CI: -13.23, -5.70).

    “total cholesterol (WMD: -9.47; 95% CI: - 13.23, -5.70) and LDL-cholesterol (LDL-C) concentrations (WMD: -6.25; 95% CI: -9.30, -3.21)”

    Review

    The Effects of L-Carnitine Supplementation on Serum Lipids: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

    Current pharmaceutical design

  8. Levocarnitine showed no clear effect on total cholesterol in humans (hemodialysis patients) (SMD -0.11, 95% CI -0.31 to 0.09).

    “The use of L-carnitine was not associated with a reduction in the total cholesterol (SMD, -0.11; 95% CI, -0.31 to 0.09)”

    Reviewhemodialysis patients

    Influence of L-carnitine supplementation on serum lipid profile in hemodialysis patients: a systematic review and meta-analysis

    Kidney & blood pressure research

More on Levocarnitine

Fish oil

no changein humans3downin humans2upin humans1downin rats1−27%

7 studies
  1. Fish oil decreases total cholesterol in humans (perimenopausal women receiving nutritional advice adapted to Mediterranean diet) (-26.86%).

    “Total Cholesterol (-26,86 %; p≤0.001), Triglycerides (-25,38%; p≤0.001) and LDL-Cholesterol (-6.5 %; p≤0.01).”

    Human trialperimenopausal women receiving nutritional advice adapted to Mediterranean dietfish oil1g per day60 daysfemalesn = 98

    Mediterranean Diet Supplemented with Omega-3 Improves Climacteric Symptoms and Cardiometabolic Risk Factors in Perimenopausal Women: A Randomized Controlled Trial

    Current Women s Health Reviews

  2. Fish oil decreases total cholesterol in humans (participants with lower adiponectin concentration at baseline).

    “participants with lower adiponectin concentration showed a higher reduction of total cholesterol, LDL, LDL/high-density lipoprotein ratio, LDL/apo B, and LDL(-)”

    Human trialparticipants with lower adiponectin concentration at baselineserum3 g/d2-mo

    The benefits of ω-3 supplementation depend on adiponectin basal level and adiponectin increase after the supplementation: A randomized clinical trial

    Nutrition (Burbank, Los Angeles County, Calif.)

  3. Fish oil increases total cholesterol in apoE4 carriers relative to common E3/E3 genotype.

    “In apoE4 individuals, a significant increase in total cholesterol and a trend toward a reduction in HDL-C relative to the common homozygous E3/E3 profile was evident.”

    Human trialin apoE4 carriers relative to common E3/E3 genotypecapsules3.0 g eicosapentaenoic acid/docosahexaenoic acid per day6 weeksmales

    ApoE polymorphism and fish oil supplementation in subjects with an atherogenic lipoprotein phenotype

    Arteriosclerosis, thrombosis, and vascular biology

  4. Fish oil showed no clear effect on total cholesterol in humans (treated hypertensives).

    “there was no difference between the phases for plasma concentrations of total or high-density lipoprotein (HDL) cholesterol”

    Human trialtreated hypertensivescapsules (Lipitac)plasma15 g/day8 weeksn = 20

    Lack of effect of fish oil supplementation on blood pressure in treated hypertensives

    Journal of hypertension

  5. Fish oil showed no clear effect on total cholesterol in humans (mild non-insulin-dependent diabetes mellitus).

    “There was no significant change in fasting plasma total, high-density lipoprotein, and low-density lipoprotein cholesterol levels.”

    Human trialmild non-insulin-dependent diabetes mellitus10 g daily3 wkn = 10

    Effects of fish oil supplementation on glucose and lipid metabolism in NIDDM

    Diabetes

  6. Fish oil decreases total cholesterol in rats (significantly reduced in both fish oil groups vs corn oil groups; p < 0.001).

    “The plasma's total cholesterol was significantly reduced in both FO Groups versus the CO Groups (p < 0.001)”

    Animals2.8 g/kg body weight4 monthsfemales

    Fish Oil Consumption: Its Effects on Bone and Blood Parameters of the Ovariectomized Rat Model of Osteopenia

    Nutrients

  7. Fish oil showed no clear effect on total cholesterol in humans (hyperlipidemic subjects) (-0.01 mmol/L, 95% CI: -0.03 to 0.01).

    “no change in total cholesterol (-0.01 mmol/L, 95% CI: -0.03 to 0.01)”

    Reviewhyperlipidemic subjects3.25 g daily

    Benefits of fish oil supplementation in hyperlipidemia: a systematic review and meta-analysis

    International journal of cardiology

More on Fish oil

Resistance training

downin humans5

5 studies
  1. Resistance training decreases total cholesterol in humans.

    “After 12 weeks of RT, a significant reduction was observed in adiponectin concentrations (time effect, p = 0.049; η2 = 0.131) and total cholesterol (time effect, p = 0.047; η2 = 0.134).”

    Human trial12 weeksfemalesn = 30

    Effects of 12-Week Resistance Training on Metabolic and Immune Responses in Normal-Weight and Older Women with Obesity

    International journal of molecular sciences

  2. Resistance training decreases total cholesterol in humans (p < 0.05).

    “CEG showed a significant reduction only in total cholesterol.”

    Human trialbloodtwo monthsn = 7

    Two Months of Active Video Game Training Improves Selected Lipid Profile Markers in Older Adults: A Preliminary Study

    Geriatrics (Basel, Switzerland)

  3. Resistance training decreases total cholesterol in humans (271.8 ± 75.7 vs. 217.2 ± 52.2 mg/dL, p < 0.01, d = -0.8).

    “Significant improvements were also found in total cholesterol (271.8 ± 75.7 vs. 217.2 ± 52.2 mg/dL; p < 0.01 and d = -0.8)”

    Human trial10 weeksfemalesn = 12

    Resistance training maintains physical function but does not prevent changes in body composition and biochemical markers after detraining in aging adults

    Journal of bodywork and movement therapies

  4. Resistance training decreases total cholesterol in humans (Untrained older women; change after exercise intervention).

    “TC, LDL, GLU and CRP were reduced significantly (p < 0.05) after exercise intervention in the exercise group.”

    Human trialUntrained older women; change after exercise interventionsingle-setSingle sets of 10–15 repetitions in 8 exercises, 3 times per week12 weeksfemales

    Resistance training performed with single-set is sufficient to reduce cardiovascular risk factors in untrained older women: The randomized clinical trial. Active Aging Longitudinal Study

    Archives of gerontology and geriatrics

  5. Resistance training decreases total cholesterol in humans (P < .01).

    “RE significantly reduced the elevation of TC (P < .01) and LDL-C (P < .05) indices in the elderly population”

    Review

    Effects of different exercise modalities on lipid profile in the elderly population: A meta-analysis

    Medicine

More on Resistance training

Exercise

downin humans4

4 studies
  1. Exercise decreases total cholesterol in humans (sedentary middle-aged women) (-8.2%, p < 0.001).

    “Significant improvements were observed in total cholesterol (−8.2%, p < 0.001), LDL cholesterol (−11.6%, p < 0.001), HDL cholesterol (+4.1%, p < 0.001)”

    Human trialsedentary middle-aged women20-weekfemalesn = 15

    Effects of Individualized Periodized Combined Training on Lipid Profile and Atherogenic Cardiovascular Risk in Sedentary Middle-aged Colombian Women

    World Journal of Public Health

  2. Exercise decreases total cholesterol in humans (metabolic syndrome).

    “while DBP, TC, TG, and LDL-C levels were significantly improved only in the HRLAT and HALRT groups (p < 0.05).”

    Human trialmetabolic syndrome12 weeksn = 85

    Benefits of different combinations of aerobic and resistance exercise for improving plasma glucose and lipid metabolism and sleep quality among elderly patients with metabolic syndrome: a randomized controlled trial

    Endocrine journal

  3. Exercise decreases total cholesterol in humans (-26.67 mg/dL, 95% CI: -34.92, -18.42).

    “Exercise significantly reduced triglycerides (TG) (-8.56 mg/dL, 95% CI: -16.72, -0.40), total cholesterol (TC)(-26.67 mg/dL, 95% CI: -34.92, -18.42)”

    Reviewfemales

    Effects of exercise on metabolic risk, cardiovascular fitness, and body composition in elderly women of the past decade: a systematic review and meta-analysis

    Journal of the International Society of Sports Nutrition

  4. Exercise decreases total cholesterol in older adults with cognitive frailty.

    “four studies showing improvements with exercise intervention via a decrease in total cholesterol, triglycerides, and low-density lipoprotein and an increase in high-density lipoprotein”

    Reviewin older adults with cognitive frailty

    Changes in cardiovascular-health blood biomarkers in response to exercise intervention among older adults with cognitive frailty: A scoping review

    Frontiers in physiology

More on Exercise

Time-restricted feeding

downin humans2no changein humans1downin rats1

4 studies
  1. Time-restricted feeding decreases total cholesterol in humans.

    “TRF was linked with significant reductions in triglycerides (P = 0.003) and total cholesterol (P = 0.001) levels.”

    Human trial12 weeks

    Ten-Hour Time-Restricted Feeding Improves Post-Kidney Transplantation Dyslipidemia:a randomized controlled trial

    Research SquarePreprint

  2. Time-restricted feeding decreases total cholesterol in diet-induced obese rats after body-weight adjustment.

    “After body-weight adjustment, total cholesterol and triglycerides were reduced in fasting groups”

    Animalsin diet-induced obese rats after body-weight adjustmentfour weeks

    Circadian Timing, Rather than Hydration Status, Determines Metabolic Adaptation to Ramadan-like Fasting in Diet-Induced Obese Rats

    Nutrients

  3. Time-restricted feeding decreases total cholesterol in humans (6%-7%).

    “partially lower total cholesterol (6%-7%)”

    Review

    Time-restricted eating as a potential strategy for healthy lifespan: an evaluation of current evidence

    Frontiers in medicine

  4. Time-restricted feeding showed no clear effect on total cholesterol in adults with overweight and obese (MD = -1.09~1.20 mg/dL, 95% CI -4.31~5.47).

    “it did not alter the total cholesterol, high-density lipoprotein, and triglycerides (MDpooled = -1.09~1.20 mg/dL, 95% CI -4.31~5.47, p > 0.05)”

    Reviewin adults with overweight and obesen = 1,288

    The Effects of Time-Restricted Eating on Fat Loss in Adults with Overweight and Obese Depend upon the Eating Window and Intervention Strategies: A Systematic Review and Meta-Analysis

    Nutrients

More on Time-restricted feeding

Aerobic exercise

downin humans4

4 studies
  1. Aerobic exercise decreases total cholesterol in humans (obese postmenopausal women).

    “Both exercise groups showed favourable changes in metabolic, inflammatory, and menopausal outcomes compared with the control group.”

    Human trialobese postmenopausal womenthree times weeklysix weeksfemalesn = 20

    Metabolic and inflammatory correlates of menopausal symptom improvement following morning and evening aerobic exercise in obese postmenopausal women

    Comparative Exercise Physiology

  2. Aerobic exercise decreases total cholesterol in humans.

    “The results revealed that 6 months of moderate aerobic training significantly reduced BMI, fasting blood sugar, glycosylated haemoglobin, hs-CRP, and lipid profile parameters, such as T-Cholest, TG, and LDL-C, in the patients with prediabetes (P < 0.05) group 1 and those with diabetes group 2 (P < 0.01”

    Human trial6 monthsn = 58

    The effects of supervised aerobic training on dyslipidaemia among diabetic older patients

    BMC endocrine disorders

  3. Aerobic exercise decreases total cholesterol in humans (-9.2% (P = 0.001)).

    “significant reductions in total cholesterol (P = 0.001, -9.2%) and triglyceride (P = 0.007, -32.4%) concentrations postexercise.”

    Human trial3 consecutive daysmalesn = 11

    Responses of LDL and HDL particle size and distribution to omega-3 fatty acid supplementation and aerobic exercise

    Journal of applied physiology (Bethesda, Md. : 1985)

  4. Aerobic exercise decreases total cholesterol in humans (P < .05).

    “AE significantly reduced TC (P < .05), triglycerides (P < .01), and LDL-C (P < .01), while increasing HDL-C (P < .01) in the elderly population.”

    Review

    Effects of different exercise modalities on lipid profile in the elderly population: A meta-analysis

    Medicine

More on Aerobic exercise

Atorvastatin

downin humans2no changein humans1no changein O. cuniculus1

4 studies
  1. Atorvastatin showed no clear effect on total cholesterol in humans (compared with placebo, fully adjusted model).

    “atorvastatin did not improve frailty status, frailty-related components, total cholesterol, or serum myostatin levels compared with placebo in PLHIV receiving ART”

    Human trialcompared with placebo, fully adjusted model40 mg once daily12 weeks

    Effect of atorvastatin on frailty-related outcomes, body composition and biochemical markers in people living with HIV: A randomized, double-blind, placebo-controlled clinical trial

    Narra X

  2. Atorvastatin decreases total cholesterol in humans (early menopausal women with hypercholesterolemia; compared to baseline).

    “both Xuezhikang and atorvastatin significantly reduced the levels of total cholesterol, triglycerides, low density cholesterol compared to baseline (all P<0.01).”

    Human trialearly menopausal women with hypercholesterolemia; compared to baselineserum10 mg/d8 weeksfemales

    Effect of "Natural Polypill", Xuezhikang on Serum Cholesterol Metabolism Markers in Early Menopausal Women with Hypercholesterolemia

    Chinese journal of integrative medicine

  3. Atorvastatin decreases total cholesterol in humans (decreased significantly).

    “Serum total cholesterol and LDL-cholesterol levels decreased significantly.”

    Human trial10 mg/day8 weeksn = 14

    Reduction of serum ubiquinol-10 and ubiquinone-10 levels by atorvastatin in hypercholesterolemic patients

    Journal of atherosclerosis and thrombosis

  4. Atorvastatin showed no clear effect on total cholesterol in WHHL rabbits.

    “No effect on total cholesterol, triglycerides, HDL or LDL was observed.”

    Animalsin WHHL rabbits2.5 mg/kg/daymalesn = 34

    A non-hypocholesterolemic atorvastatin treatment improves vessel elasticity by acting on elastin composition in WHHL rabbits

    Atherosclerosis

More on Atorvastatin

All 273

Effects

24

Cognitive function

downin humans2upin humans1mediatesin humans1no changein humans1

4 studies
  1. Total cholesterol is linked with worse cognitive function in APOE ε4 carriers (-0.020 (SD 0.009, p=0.035)).

    “only in ε4 carriers that higher TC levels were significantly associated with accelerated CD, -0.020 (0.009,0.035)”

    Humansin APOE ε4 carriersn = 3,496

    Longitudinal associations between lipid panel and cognitive decline modified by APOE 4 carrier status in biracial community-dwelling older adults: Findings from the Chicago health and aging project

    Archives of gerontology and geriatrics

  2. Total cholesterol is linked with worse cognitive function in CDR >= 1 group.

    “associated with improved cognition in women but linked to cognitive decline in men.”

    Humansin CDR >= 1 groupmalesn = 466

    Sex-specific associations between serum lipid levels and cognitive performance in older adults: results from a cross-sectional real-world study

    Aging clinical and experimental research

  3. Total cholesterol is linked with better cognitive function in CDR >= 1 group.

    “For CDR ≥ 1, TC and HDL-C were associated with improved cognition in women”

    Humansin CDR >= 1 groupfemalesn = 817

    Sex-specific associations between serum lipid levels and cognitive performance in older adults: results from a cross-sectional real-world study

    Aging clinical and experimental research

  4. Total cholesterol is linked with cognitive function in humans (mediating the APOE ε2 effect on cognition; whole sample and females).

    “total cholesterol and low-density lipoprotein cholesterol mediated the protective effect of APOE ε2 on cognition in the whole sample and total cholesterol in females”

    Humansmediating the APOE ε2 effect on cognition; whole sample and femalesn = 648

    Sex-Specific Protective Effects of APOE ε2 on Cognitive Performance

    The journals of gerontology. Series A, Biological sciences and medical sciences

  5. Total cholesterol was not clearly linked with cognitive function in carriers of the APOE4 allele.

    “No significant associations between cognitive performance and lipid profile were found for carriers of the APOE4 allele.”

    Humansin carriers of the APOE4 allelen = 185

    Better memory functioning associated with higher total and low-density lipoprotein cholesterol levels in very elderly subjects without the apolipoprotein e4 allele

    The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry

Subarachnoid hemorrhage

no changein humans1HR 1.06

1 study
  1. Total cholesterol was not clearly linked with subarachnoid hemorrhage in humans (Genetically predicted lipid trait; analysis adjusted for lipid-lowering therapy) (HR 1.06 [0.71-1.60]).

    “TC (HR 1.06 [0.71-1.60])”

    HumansGenetically predicted lipid trait; analysis adjusted for lipid-lowering therapyn = 486,603

    Lipid Traits and Risk of Subarachnoid Haemorrhage: A Systematic Review and Mendelian Randomization Study in UK Biobank

    Translational stroke research

More on Subarachnoid hemorrhage

Estimated glomerular filtration rate

no changein humans1

1 study
  1. Total cholesterol was not clearly linked with estimated glomerular filtration rate in humans.

    “No statistically significant associations were observed for total cholesterol or LDL.”

    Humansn = 317

    A Clinical Evaluation of Age and Metabolic Factors Affecting the Estimated Glomerular Filtration Rate

    JURNAL BIOLOGI TROPIS

More on Estimated glomerular filtration rate

White matter hyperintensities

downin humans1

1 study
  1. Total cholesterol is linked with lower white matter hyperintensities in humans (controlled total cholesterol vs uncontrolled) (0.176 vs. 0.939 mL/year).

    “slower progression (e.g., controlled total cholesterol: 0.176 vs. 0.939 mL/year, p = 0.007)”

    Humanscontrolled total cholesterol vs uncontrolledbrainn = 1,146

    Region-specific vulnerability to vascular risk factors and modifiable protective influences on white matter hyperintensities

    Communications medicine

More on White matter hyperintensities

Global cognition

no changein humans1

1 study
  1. Total cholesterol was not clearly linked with global cognition in humans after adjusting for genetic and shared environmental factors.

    “In the twins modeling, after adjusting for genetic and shared environmental factors, the associations disappeared.”

    Humansafter adjusting for genetic and shared environmental factors

    Associations between Cardiovascular Risk Factors and Cognitive Function: A Cross-Sectional Study of Twins in the UK

    Gerontology

Rate of brain aging

upin humans1

1 study
  1. Total cholesterol is linked with higher rate of brain aging in humans (via aorta and carotid structures).

    “elevated total cholesterol level was found to accelerate brain aging by affecting the aorta and carotid structures.”

    Humansvia aorta and carotid structures

    Cardiovascular imaging reveals pathways linking cardiovascular risk factors to brain aging and cognition

    Neurobiology of aging

Diastolic blood pressure

mediatesin humans1

1 study
  1. Total cholesterol is linked with diastolic blood pressure in humans (relationship between smoking/vaping and diastolic BP) (6.7% mediation effect).

    “Mediation analysis revealed that higher total cholesterol partly mediated (6.7% mediation effect) the relationship between smoking/vaping and diastolic BP.”

    Humansrelationship between smoking/vaping and diastolic BPn = 6,262

    Tobacco and electronic cigarette use with hypertension and the mediating effect of dyslipidemia - the NHANES study

    American journal of physiology. Heart and circulatory physiology

More on Diastolic blood pressure

Digit Symbol Coding score

no changein humans1

1 study
  1. Total cholesterol was not clearly linked with digit Symbol Coding score in air pollutant-cognition relationship (no evidence of mediation).

    “there was no evidence of mediation by cholesterol levels.”

    Humansin air pollutant-cognition relationshipn = 1,518

    Air Pollution, Blood Lipids, And Cognitive Performance From The Multi-Ethnic Study Of Atherosclerosis (MESA)

    GSA 2025 abstract

Alzheimer's disease

mediatesin humans1

1 study
  1. Total cholesterol is linked with Alzheimer's disease in humans (mediating effect of BMR on Alzheimer's disease) (38.65% mediation (95% CI 15.34%–61.97%)).

    “the largest contributor was total cholesterol (38.65% mediation; 95%CI 15.34%, 61.97%)”

    Humansmediating effect of BMR on Alzheimer's disease

    Mendelian randomization implicates blood lipids as an actionable mediator of the effect of basal metabolic rate on Alzheimer's disease

    AAIC 2025 abstract

More on Alzheimer's disease

Dementia

downin humans1

1 study
  1. Total cholesterol is linked with less dementia in patients with chronic kidney disease.

    “elevated LDL (>100 mg/dL), total cholesterol (≥200 mg/dL), and triglycerides (≥150 mg/dL) were protective factors”

    Humansin patients with chronic kidney disease

    Lipid profile reversely predicts the development of dementia in patients with chronic kidney disease‐ from TMUCRD database

    AAIC 2025 abstract

More on Dementia

All 24

Upstream

15

Age

upin humans1downin humans1+38%

2 studies
  1. Age is linked with higher total cholesterol in humans (+37.8%).

    “With age, plasma total cholesterol levels increased by 37.8% in men and by 34.1% in women.”

    Humansmales

    Gender and age-related features of total cholesterol concentration in the blood of the working-age population in Yaroslavl

    Siberian Journal of Life Sciences and Agriculture

  2. Age is linked with lower total cholesterol in humans.

    “we observed a decreasing trend in LnTAG (natural logarithm of Triacylglycerol) and total Cholesterol (CHR) levels with increasing age”

    Humansn = 8,746

    A study of baseline data from SPRINT: Exploring lipid profile changes in middle-aged and elderly patients

    Lipids

Endotrophin

mediatesin humans1

1 study
  1. Endotrophin mediates total cholesterol in humans (exploratory mediation analysis of the fat mass effect on total cholesterol) (15% [4, 51] of the effect mediated).

    “Exploratory mediation analyses showed that endotrophin mediated 15% [4, 51] of the effect of fat mass on total cholesterol.”

    Human trialexploratory mediation analysis of the fat mass effect on total cholesterol

    Dynamic regulation of circulating endotrophin by changes in fat mass in humans

    Metabolism: clinical and experimental

More on Endotrophin

Time

downin humans1

1 study
  1. time is linked with lower total cholesterol in humans (-0.0027 mmol/L, p = 0.046).

    “average total cholesterol decreased significantly worldwide (weighted annual change: -0.0027 mmol/L, p = 0.046)”

    Humansmultidecade

    A Hierarchical Nonlinear Modelling Framework of Uncertainty Surveillance of Aggregated Global Cholesterol

    Cardiology and Angiology An International Journal

Menopause

upin humans1

1 study
  1. Menopause is linked with higher total cholesterol in humans (p < 0.05).

    “Postmenopausal women exhibited significantly higher TC, TG, LDL, and BMI, along with lower HDL compared to other groups (p < 0.05).”

    Humansfemales

    A comparative Study of Serum Lipid Profile and Body Mass Index in Premenopausal, Perimenopausal and Postmenopausal Female Patients Attending IPD/OPD at District Hospital, North Goa

    International Journal of Current Pharmaceutical Review and Research

Hypothyroidism

upin humans1

1 study
  1. Hypothyroidism is linked with higher total cholesterol in humans (compared to euthyroid controls) (p<0.05).

    “Women with hypothyroidism exhibited significantly elevated levels of TC, TG, VLDL, and LDL-C along with reduced HDL-C, compared to euthyroid controls (p<0.05).”

    Humanscompared to euthyroid controlsserumfemalesn = 150

    Effect of hypothyroidism on lipid profile in pre- and post-menopausal women in Erbil city

    Qalaai Zanist Scientific Journal

More on Hypothyroidism

Body mass index

upin humans1

1 study
  1. Body mass index is linked with higher total cholesterol in Chinese adults (per 1-SD body mass index increase, β-coefficient for TC: 3.43 [95% CI: 3.15-3.71] vs 2.71 [95% CI: 2.48-2.94] mg/dL).

    “Obesity indicators were positively associated with elevated lipid levels (all P < 0.001)”

    Humansin Chinese adultsn = 83,487

    Chinese Population-Wide Lipid Trajectories From Age 20 to 85 Years: Sex- and Adiposity-Specific Patterns

    JACC. Asia

More on Body mass index

CGAS

downin mice1

1 study
  1. CGAS decreases total cholesterol in mice (shown by knockout).

    “Conversely, total cholesterol levels were consistently and significantly elevated across all age groups”

    Animalsshown by knockoutmales

    Lifelong cGAS deficiency leads to altered lipid storage and cholesterol homeostasis

    Biological research

More on CGAS

STING1

downin mice1

1 study
  1. STING1 decreases total cholesterol in mice (Healthy physiological conditions; shown by knockout compared with WT).

    “STINGKO mice exhibited markedly increased circulation levels of triglycerides and total cholesterol.”

    AnimalsHealthy physiological conditions; shown by knockout compared with WTblood

    Loss of stimulator of interferon genes (STING) promotes accumulation of cholesterol and triglycerides throughout life in mice

    Biological research

More on STING1

SIRT1

downin humans1

1 study
  1. SIRT1 is linked with lower total cholesterol in humans (G allele carriers) (p = 0.030).

    “female carrying rs1467568 had lower levels of total cholesterol (p = 0.030), triglycerides (p = 0.026) and LDL cholesterol (p = 0.013).”

    HumansG allele carriersfemalesn = 405

    Analysis of SIRT1 genetic variants in young Mexican individuals: relationships with overweight and obesity

    Frontiers in genetics

More on SIRT1

8-iso-PGF2α

mediatesin humans1

1 study
  1. 8-iso-PGF2α is linked with total cholesterol in humans (36.63%).

    “Mediation analyses verified that 8-iso-PGF2α partially mediated the correlations between blood As with TC (36.63%) and LDL-C (34.03%).”

    Humansserumn = 360

    Association between blood arsenic concentration and dyslipidemia: Mediating effect of lipid peroxidation in the elderly

    Journal of trace elements in medicine and biology : organ of the Society for Minerals and Trace Elements (GMS)

More on 8-iso-PGF2α

All 15

Associations

210

Mortality

downin humans4upin humans3HR 0.67–8.68

7 studies
  1. Total cholesterol is linked with a lower risk of mortality in humans (HR 0.993, 95% CI 0.986-1.000).

    “total cholesterol (P=0.003, HR=0.969, 95% CI=0.949-0.989 and P=0.046, HR=0.993, 95% CI=0.986-1.000, respectively) showed a decreased risk of mortality”

    Humans596±44 daysn = 112

    Clinical characteristics of atrial fibrillation in nonagenarian population and relationship with mortality

    Minerva cardiology and angiology

  2. Total cholesterol is associated with mortality in humans (Chinese participants; multivariable Cox regression) (HR 0.88, 95% CI 0.78–1.00).

    “In oldest old aged 85 and older, serum total cholesterol levels are inversely associated with all-cause mortality.”

    HumansChinese participants; multivariable Cox regressionserum3 yearsn = 903

    Association between total cholesterol and all-cause mortality in oldest old: a national longitudinal study

    Frontiers in endocrinology

  3. Total cholesterol is linked with a lower risk of mortality in humans (geriatric patients with hip fractures) (HR = 0.67, 95% CI: 0.53-0.85).

    “Linear multivariate Cox regression models showed that TC levels were associated with mortality (hazard ratio (HR) = 0.67; 95% confidence interval (95% CI): 0.53-0.85; p = 0.001 after adjusting for confounding factors).”

    Humansgeriatric patients with hip fracturesn = 339

    Association between total cholesterol and all-cause mortality in geriatric patients with hip fractures: A prospective cohort study with 339 patients

    Advances in clinical and experimental medicine : official organ Wroclaw Medical University

  4. Total cholesterol is associated with mortality in humans (men not on statin therapy, adjusted for comorbidities; per 1 mmol/L decrease) (HR 1.22, 95% CI 1.03 to 1.44).

    “and mortality (HR 1.22, 95% CI 1.03 to 1.44, p=0.02) adjusted for comorbidities”

    Humansmen not on statin therapy, adjusted for comorbidities; per 1 mmol/L decreaseper 1 mmol/L decreasemean follow-up 6.4±2.7 yearsmalesn = 731

    Low total cholesterol is associated with increased major adverse cardiovascular events in men aged ≥70 years not taking statins

    Heart (British Cardiac Society)

  5. Total cholesterol is associated with mortality in humans (Borderline-high total cholesterol (5.18–6.21 mmol/l) versus <5.18 mmol/l) (HR 0.71, 95% CI 0.61–0.83).

    “borderline-high (5.18-6.21 mmol/l) and high (≥6.22 mmol/l) total cholesterol were associated with a decreased risk of all-cause mortality”

    HumansBorderline-high total cholesterol (5.18–6.21 mmol/l) versus <5.18 mmol/lMedian follow-up 7.5 years63.7% womensn = 3,090

    Serum total cholesterol and risk of cardiovascular and non-cardiovascular mortality in old age: a population-based study

    BMC geriatrics

  6. Total cholesterol is associated with mortality in humans (statin-treated) (HR 1.53, 95% CI 1.43-1.64).

    “Compared with TC values of 4.5-5.4 mmol/L, TC values <3.0 mmol/L were associated with higher mortality (statin treated hazard ratios 1.53, 95% confidence interval 1.43-1.64, p < .001”

    Humansstatin-treatedn = 99,758

    Trajectory of Total Cholesterol in the Last Years of Life Over Age 80 Years: Cohort Study of 99,758 Participants

    The journals of gerontology. Series A, Biological sciences and medical sciences

  7. Total cholesterol is associated with mortality in humans (Lowest quartile: HR 8.68, 95% CI 2.14-35.21).

    “the lowest quartile of total cholesterol showed independent association with mortality (HR 8.68, CI 2.14-35.21, p<0.01).”

    HumansPrevalent peritoneal dialysis patients; lowest quartile of total cholesterol; adjusted analysis36 monthsn = 106

    Nutritional predictors of mortality in prevalent peritoneal dialysis patients

    Acta biochimica Polonica

Alzheimer's disease

upin humans5downin humans1OR 0.867–2.5

6 studies
  1. Total cholesterol is associated with Alzheimer's disease in humans.

    “higher total cholesterol and type 2 diabetes were associated with lower and higher AD risk, respectively, in males.”

    HumansGenetically predicted total cholesterol; Mendelian randomization with inconsistent sensitivity-analysis supportmales

    Sex differences in genetic liability to modifiable Alzheimer's disease risk factors

    medRxivPreprint

  2. Total cholesterol is associated with Alzheimer's disease in humans (Genetically predicted total cholesterol).

    “Total cholesterol (TC) was positively associated with Alzheimer disease (AD) and dementia.”

    HumansGenetically predicted total cholesterol

    Cholesterol links to dementia varied by genetic region

    Genes

  3. Total cholesterol is linked with a higher risk of Alzheimer's disease in humans (Mendelian randomization; verbal risk direction conflicts with the reported odds ratio) (OR 0.867, 95% CI 0.776–0.968; P = .011).

    “Higher levels of total cholesterol (OR: 0.867, 95% CI: 0.776-0.968, P = .011), triglycerides (OR:0.870, 95% CI: 0.767-0.985, P = .028) were connected to increased AD risk.”

    HumansMendelian randomization; verbal risk direction conflicts with the reported odds ratio

    The causal association between hyperlipidemia and Alzheimer disease: A combined NHANES and Mendelian randomization study

    Medicine

  4. Total cholesterol is associated with Alzheimer's disease in humans (lowest VIM quintile of total cholesterol) (OR 2.5 (1.5-4.0)).

    “the lowest VIM quintile of total cholesterol [odds ratio: 2.5(1.5-4.0: P < 0.001)]”

    Humanslowest VIM quintile of total cholesterolblood

    Lipid trajectories improve risk models for Alzheimer's disease and mild cognitive impairment

    Journal of lipid research

  5. Total cholesterol is associated with Alzheimer's disease in humans.

    “elevated fasting insulin and total cholesterol levels were associated with an increased risk of dementia in Alzheimer's disease”

    Humans

    Impact of diabetes mellitus on the risk of Alzheimer's disease: a mendelian randomization study

    BMC neurology

  6. Total cholesterol is associated with Alzheimer's disease in humans (OR 1.21 per mg/dL greater total cholesterol, 95% CI 1.09–54.05).

    “1.21 for AD (1.09-54.05)”

    HumansMendelian randomization using APOE as a genetic instrument; APOE4+ compared with APOE3 carriersn = 1,534

    Total Cholesterol and APOE-Related Risk for Alzheimer's Disease in the Alzheimer's Disease Neuroimaging Initiative

    Journal of Alzheimer's disease : JAD

  7. Alzheimer's disease is associated with total cholesterol in humans (Compared with cognitively normal controls).

    “Those with AD and late MCI (ps < 0.001) had higher total cholesterol than the control group.”

    HumansCompared with cognitively normal controls

    Total Cholesterol and APOE-Related Risk for Alzheimer's Disease in the Alzheimer's Disease Neuroimaging Initiative

    Journal of Alzheimer's disease : JAD

More on Alzheimer's disease

Dementia

upin humans3downin humans3OR 0.674

6 studies
  1. Total cholesterol is associated with dementia in humans (heterogeneous community of older adults) (r = -0.244, p = 0.029).

    “total cholesterol levels showed a significant negative correlation with dementia risk (r = -0.244; p = 0.029)”

    Humansheterogeneous community of older adultsn = 80

    Dementia Risk Profile Among Older Adults at GKI Gunung Sahari: The Role of Lifestyle and Health Factors

    Jurnal Pinang Masak

  2. Total cholesterol is linked with a higher risk of dementia in humans (univariable Mendelian randomization, inverse variance weighting).

    “Elevated total cholesterol (TC) increased dementia, ADD, and DLB.”

    Humansunivariable Mendelian randomization, inverse variance weighting

    Statins cut Alzheimer's risk but raise other dementia risks

    Journal of Alzheimer's disease reports

  3. Total cholesterol is associated with dementia in humans.

    “We observed a weaker association between total cholesterol and dementia incidence”

    Humansn = 1,853,954

    Blood cholesterol and risk of dementia in more than 1·8 million people over two decades: a retrospective cohort study

    The lancet. Healthy longevity

  4. Total cholesterol is linked with a lower risk of dementia in humans (OR 0.674, p = .005).

    “total cholesterol (TC) (OR: 0.674, p = .005) was a protective factor for dementia”

    Humans

    A probability formula derived from serum indicators, age, and comorbidities as an early predictor of dementia in elderly Chinese people

    Brain and behavior

  5. Total cholesterol is associated with dementia in humans (HR=4.21; 95% CI 1.28 to 13.85).

    “Among men only, TC decline from first visit was significantly associated with increased dementia risk (HR=4.21; 95% CI 1.28 to 13.85).”

    Humansmedian time of around 25 yearsmales

    Statins and serum cholesterol's associations with incident dementia and mild cognitive impairment

    Journal of epidemiology and community health

  6. Total cholesterol is associated with dementia in humans.

    “A decline in serum total cholesterol levels may be associated with early stages in the development of dementia.”

    Humans26 yearsmales

    Twenty-six-year change in total cholesterol levels and incident dementia: the Honolulu-Asia Aging Study

    Archives of neurology

  7. Dementia is associated with total cholesterol in humans.

    “Cholesterol levels in men with dementia and, in particular, those with Alzheimer disease had declined at least 15 years before the diagnosis”

    Humans26 yearsmales

    Twenty-six-year change in total cholesterol levels and incident dementia: the Honolulu-Asia Aging Study

    Archives of neurology

More on Dementia

Menopause

upin humans6

6 studies
  1. Menopause is associated with total cholesterol in post-menopausal compared to pre-menopausal women.

    “There is statistically significant raised values of TC, TAG and LDL-c values were observed among post-menopausal participants”

    Humansin post-menopausal compared to pre-menopausal womenfemalesn = 100

    Association of Atherogenic Index Among Postmenopausal Bangladeshi Women

    Journal of Netrokona Medical College

  2. Menopause is associated with total cholesterol in humans (menopause transition and postmenopause).

    “whereas CHOL and LDLC levels were higher in both the menopause transition and postmenopause stages.”

    Humansmenopause transition and postmenopausefemales

    Preliminary lipidomics and transcriptomics reveals stage-specific dynamic metabolic patterns from menopause transition to postmenopause

    Frontiers in endocrinology

  3. Menopause is associated with total cholesterol in humans (Postmenopausal compared with premenopausal women).

    “Post-menopausal women demonstrated significantly elevated total cholesterol, triglycerides, LDL-C, Non-HDL cholesterol, AIP, CRI-I, and CRI-II compared to pre-menopausal controls (p<0.001).”

    HumansPostmenopausal compared with premenopausal womenfemales

    Evaluating Non-HDL Cholesterol and Atherogenic Indices as Key Predictors of Cardiovascular Risk in Post-Menopausal Women

    TAJ Journal of Teachers Association

  4. menopause is associated with total cholesterol in humans (menopausal transition, compared with matched men) (+16.7 vs -3.1 mg/dL in women versus men).

    “Compared with the men, the women showed a greater increase in serum total cholesterol (+16.7 vs -3.1 mg/dL, P < 0.001)”

    Humansmenopausal transition, compared with matched men3 to 6 years before and after menopause agefemalesn = 263

    Changes in cardiovascular disease risk factors during menopausal transition in Japanese women: the Circulatory Risk in Communities Study (CIRCS)

    Menopause (New York, N.Y.)

  5. Menopause is associated with total cholesterol in humans (adjusted for confounders) (0.2 to 0.4 mmol/L higher TC, 0.1 to 0.3 mmol/L higher LDL-c).

    “At all ages between 46 and 55 years, and after adjustment for confounders, naturally postmenopausal women had 0.2 to 0.4 mmol/L higher TC and 0.1 to 0.3 mmol/L higher LDL-c levels compared to premenopausal women in the same age range.”

    Humansadjusted for confoundersfemales

    Unraveling the associations of age and menopause with cardiovascular risk factors in a large population-based study

    BMC medicine

  6. Menopause is associated with total cholesterol in humans.

    “Independent of aging, menopausal status is associated with elevations in serum total cholesterol, LDL cholesterol, apolipoproteins, and triglycerides, and decreases in HDL cholesterol (HDL-C).”

    Reviewfemales

    Dyslipidemia in midlife women: Approach and considerations during the menopausal transition

    Maturitas

Age

upin humans3downin humans1mixedin humans1

5 studies
  1. Age is associated with total cholesterol in humans (PMOS).

    “The 30s group had significantly higher total cholesterol and glycated hemoglobin levels than the <30 group”

    HumansPMOS

    A Generational Comparison of Physical and Laboratory Findings in Patients with Polyendocrine Metabolic Ovarian Syndrome in Japan

    Journal of clinical medicine

  2. Age is associated with total cholesterol in humans (p < 0.001).

    “age and BMI were significant in influencing the level of total cholesterol (p < 0.001)”

    Humans

    ASSOCIATION OF AGE, BLOOD PRESSURE, AND BODY MASS INDEX WITH TOTAL CHOLESTEROL LEVELS AMONG MINING WORKERS

    Kesmas Indonesia

  3. Age is associated with total cholesterol in humans among Africans (p=0.035, 44.4% of >50 yrs had levels <100 mg/dL).

    “TC decreased significantly with age in Africans (p=0.035): 44.4% of >50 yrs had levels <100 mg/dL.”

    Humansamong Africansn = 112

    Cardiovascular Risk Profile Across Age Groups: A Study of Asian, African, and Hispanic Communities in Philadelphia, PA

    AHA Scientific Sessions 2025 abstract

  4. Age is associated with total cholesterol in humans.

    “Total cholesterol and LDL-cholesterol concentrations increased with age, which became attenuated between the early 30s and late 50s in men, and declined thereafter.”

    Humansmales

    Age-Related Changes in the Cardiometabolic Profiles in Singapore Resident Adult Population: Findings from the National Health Survey 2010

    PloS one

  5. Age is associated with total cholesterol in humans (lifetime multivariate analysis) (P = 6.9 × 10−4, 9.3 % of variance).

    “Total cholesterol was associated positively with multivariate age only (P = 6.9 × 10−4, 9.3 % of variance).”

    Humanslifetime multivariate analysisplasma-serumfemalesn = 120

    Interleukins 6 and 8 and abdominal fat depots are distinct correlates of lipid moieties in healthy pre- and postmenopausal women

    Endocrine

Postmenopausal status

upin humans4

4 studies
  1. Postmenopausal status is associated with total cholesterol in humans (Natural menopause) (Postmenopausal TC: 205 mg/dL).

    “Postmenopausal status was independently associated with higher TC (205 mg/dL), LDL-C (119 mg/dL), HDL-C (62 mg/dL), and TG (106 mg/dL) (all p < 0.001)”

    HumansNatural menopausefemalesn = 2,098

    Rethinking Lipid-Screening Timing Around Menopause: A Survey-Weighted Analysis of Race/Ethnicity-Specific Lipid Change in NHANES 2017-March 2020

    AHA Scientific Sessions 2026 abstract

  2. Postmenopausal status is associated with total cholesterol in humans (postmenopausal versus premenopausal women).

    “Result shows significantly higher total cholesterol (TC), triglycerides (TG), VLDL, LDL of postmenopausal women when compared with premenopausal women”

    Humanspostmenopausal versus premenopausal womenfemales

    Evaluation of Cardiovascular Risk Indices of Premenopausal and Postmenopausal Women in Delta State, Nigeria

    African Journal of Allied Health Sciences (AJAHS)

  3. Postmenopausal status is associated with total cholesterol in humans (Women with obesity; postmenopausal versus premenopausal groups) (Total cholesterol: 235.76 ± 28.78 versus 204.94 ± 46.99 mg/dL; LDL: 131.61 ± 43.20 versus 107.35 ± 25.37 mg/dL).

    “Statistical analysis showed significant differences in total cholesterol and LDL levels between the groups of postmenopausal and premenopausal women with obesity.”

    HumansWomen with obesity; postmenopausal versus premenopausal groupsfemalesn = 80

    Analysis of Differences in Total Cholesterol and LDL Levels in Premenopausal and Postmenopausal Women With Obesity

    Jurnal Ners

  4. Postmenopausal status is associated with total cholesterol in humans (Postmenopausal compared with premenopausal Saudi women).

    “Postmenopausal women exhibited significantly higher levels of total cholesterol (TC), triglycerides (TG), Ca, and PTH, and lower HDL-C and Vit-D levels compared to premenopausal women”

    HumansPostmenopausal compared with premenopausal Saudi womenserumfemalesn = 300

    Cross-sectional analysis of the association between serum calcium levels and lipid profiles and the risk of cardiovascular disease in Saudi women

    Medicine

APOE

upin humans4

4 studies
  1. APOE is associated with total cholesterol in humans across lifestyles.

    “having more APOE ε4 alleles is associated with higher total cholesterol, higher LDL cholesterol, and lower HDL cholesterol.”

    Humansacross lifestyles

    Divergent biological consequences of APOE isoforms across industrialized and non-industrial environments

    PLoS genetics

  2. APOE is associated with total cholesterol in the subjects with high serum tHcy level (p < 0.05).

    “ApoE rs429358 and rs7412 variants were observed to have the highest serum TC and TG level in the subjects with high serum tHcy level (p < 0.05).”

    Humansin the subjects with high serum tHcy levelblood

    Combined homocysteine and apoE rs429358 and rs7412 polymorphism in association with serum lipid levels and cognition in Chinese community-dwelling older adults

    BMC psychiatry

  3. APOE is associated with total cholesterol in humans (APOE4+ compared with APOE3 and APOE2+ carriers).

    “Total cholesterol was higher in APOE4+ compared to APOE3 and APOE2+ (ps < 0.04) carriers.”

    HumansAPOE4+ compared with APOE3 and APOE2+ carriersn = 1,534

    Total Cholesterol and APOE-Related Risk for Alzheimer's Disease in the Alzheimer's Disease Neuroimaging Initiative

    Journal of Alzheimer's disease : JAD

  4. APOE is associated with total cholesterol in humans (APOE4 carriers among Tsimane forager-farmers of Bolivia).

    “APOE4 is associated with 30% lower C-reactive protein, and higher total cholesterol and oxidized LDL.”

    HumansAPOE4 carriers among Tsimane forager-farmers of Bolivia50% femalesn = 1,266

    APOE4 is associated with elevated blood lipids and lower levels of innate immune biomarkers in a tropical Amerindian subsistence population

    eLife

More on APOE

Cognitive function

upin humans4

4 studies
  1. Total cholesterol is associated with cognitive function in humans.

    “total cholesterol exhibited a weak positive correlation with the ACE-III score”

    Humans

    The Role of Laboratory Parameters and Neuropsychological Assessment in Preventive Primary Care

    Preprints.orgPreprint

  2. Total cholesterol is associated with cognitive function in humans (p < 0.05).

    “TC levels were positively associated with MMSE (p < 0.05).”

    Humans

    Associations between lipid profiles and late-life cognitive impairment among oldest-old and centenarian adults

    MedComm

  3. Total cholesterol is associated with cognitive function in humans.

    “The level of total cholesterol and moderate alcohol consumption had positive relationship with CF indices in women”

    Humansfemales

    Cognitive functions and modifiable risk factors for chronic non-communicable diseases in ageing in a Russian population sample

    Advances in gerontology = Uspekhi gerontologii

  4. Total cholesterol is associated with cognitive function in humans (rG = 0.33).

    “positive genetic correlations between cognition and total cholesterol (rG = 0.33)”

    Humans

    Genetic and environmental influences on cardiovascular risk factors and cognitive function: A Chinese twin aging study

    Geriatrics & gerontology international

Cardiovascular disease

upin humans2upin silico1

3 studies
  1. Total cholesterol is associated with cardiovascular disease in humans (Offspring of coronary heart disease patients; elevated total cholesterol).

    “elevated LDL-C and CHOL levels increased the risk of CVD.”

    HumansOffspring of coronary heart disease patients; elevated total cholesterol3 monthsn = 88

    Coronary heart disease offspring: identification of short-term cardiovascular risk factors and construction of digital technology-integrated personalized health education pathways

    BMC cardiovascular disorders

  2. Cardiovascular disease is associated with total cholesterol in humans (postmenopausal women) (207.7 ± 20.4 mg/dl vs 173.8 ± 21.0 mg/dl).

    “Mean Cholesterol levels were significantly increased in the CVD group compared to controls (207.7 ± 20.4mg\dl vs control 173.8 ± 21.0 mg\dl).”

    Humanspostmenopausal womenbloodfemales

    Association of Dyslipidemia, Atherogenic Index and some Biochemical Markers with Cardiovascular Risk in Postmenopausal Women

    Tikrit Journal of Pharmaceutical Sciences

  3. Total cholesterol predicts cardiovascular disease in silico.

    “SHAP analysis revealed the relative importance of predictors, with age, TC and Digit Symbol Score (DSS) ranking highest.”

    In silicon = 4,713

    Improving 10-year cardiovascular disease risk prediction using automated machine learning

    International journal of cardiology

More on Cardiovascular disease

Coronary artery disease

upin humans3OR 4.3

3 studies
  1. Total cholesterol is linked with a higher risk of coronary artery disease in adults with metabolic syndrome (aOR 3.65, 95% CI 1.13~11.78).

    “Total cholesterol levels of 200-239 mg/dL were associated with 3.65 times higher odds (95% CI = 1.13~11.78).”

    Humansin adults with metabolic syndrome200-239 mg/dL

    Factors associated with coronary artery disease in adults with metabolic syndrome: an analysis of data from the Korea National Health and Nutrition Examination Survey

    Journal of Korean biological nursing science

  2. Total cholesterol is linked with a higher risk of coronary artery disease in humans (hypertension).

    “Advanced age, smoking, hypertension duration >10 years, and abnormal total cholesterol (TC) were independently associated with an increased risk of CHD in elderly hypertensive patients.”

    Humanshypertensionn = 428

    Predictive value of lipid levels in coronary heart disease in elderly hypertensive patients

    American journal of translational research

  3. Total cholesterol is linked with a higher risk of coronary artery disease in humans (OR 4.30 [2.41-7.65]).

    “Patients in the highest versus the lowest TC-category of the HS had an OR of 4.30 [2.41-7.65] for significant CAD at angiography”

    Humans

    Value of total cholesterol readings earlier versus later in life to predict cardiovascular risk

    EBioMedicine

More on Coronary artery disease

Estimated glomerular filtration rate

upin humans1downin humans1

2 studies
  1. Total cholesterol is associated with estimated glomerular filtration rate in humans (healthy, sedentary) (R = -0.512 to -0.582, p < 0.05).

    “There was a negative correlation between blood total cholesterol vs. eGFR (R = -0.512, R = -0.582, R = -0.531; p < 0.05)”

    Human trialhealthy, sedentaryn = 18

    Acute Effect of Three Aerobic Exercise Intensities on Glomerular Filtration Rate in Healthy Older Adults

    Diseases (Basel, Switzerland)

  2. Total cholesterol is associated with estimated glomerular filtration rate in humans (elderly individuals at nursing home).

    “There was a significant correlation between total cholesterol and LDL with eGFR (positive)”

    Humanselderly individuals at nursing homen = 76

    CORRELATION BETWEEN LIPID PROFILE, URIC ACID, HBA1C, HEMOGLOBIN, AND BLOOD GLUCOSE WITH RENAL FILTRATION RATE IN THE ELDERLY POPULATION OF HANA NURSING HOME

    Ebers Papyrus

More on Estimated glomerular filtration rate

Ceramide

upin humans1

1 study
  1. Total cholesterol is associated with ceramide in humans (adhering to a healthy dietary pattern) (13 ceramide species).

    “total cholesterol revealed a marked positive correlation with 13 ceramide species”

    Human trialadhering to a healthy dietary pattern15 g daily16-weekn = 41

    Effects of wolfberry (Lycium barbarum) consumption on the human plasma lipidome and its association with cardiovascular disease risk factors: a randomized controlled trial of middle-aged and older adults

    Frontiers in nutrition

  2. Total cholesterol is associated with ceramide in humans.

    “Among the remaining serum lipoproteins, positive associations were prominent between TC and Cer (n = 13), PC (n = 5), and SM (n = 3); LDL-C and Cer (n = 3) as well as HDL-C and PC (n = 10), Cer (n = 3), and SM (n = 2).”

    Humans16-weekn = 41

    Effects of wolfberry (Lycium barbarum) consumption on the human plasma lipidome and its association with cardiovascular disease risk factors: a randomized controlled trial of middle-aged and older adults

    Frontiers in nutrition

More on Ceramide

Multicomponent training combined with nutritional education and psychoeducation

downin humans1

1 study
  1. Multicomponent training combined with nutritional education and psychoeducation is associated with total cholesterol in humans (hypercholesterolemia; no nonintervention control group).

    “Total cholesterol and LDL-c decreased at all follow-up assessments in the hypercholesterolemic group”

    Human trialhypercholesterolemia; no nonintervention control groupthree weekly sessions12, 24, and 36 weeksfemalesn = 16

    Effects of a Multicomponent Training Program with a Multidisciplinary Approach on Body Composition, Physical Performance, Lipid Profiles, and Glucose Levels in Brazilian Older Women with Hypercholesterolemia: A Quasi-Experimental Study

    Journal of clinical medicine

More on Multicomponent training combined with nutritional education and psychoeducation

Rehabilitation exercise training

downin humans1

1 study
  1. Rehabilitation exercise training is associated with total cholesterol in humans (p < 0.001).

    “comprising decreases in CRP, total cholesterol, aHSG/fetuin-A, and GDF-15 and an increase in IGF-1 (all p < 0.001).”

    Human trialFollowing hip or knee arthroplasty; unadjusted within-participant comparison without a concurrent control groupindividualizedserum21 daysn = 42

    Effects of a 21-Day Individual Rehabilitation Exercise Training Program on CRP, Cholesterol, aHSG, GDF-15, and IGF-1 Levels in Patients After Hip or Knee Replacement Surgery

    Biomedicines

More on Rehabilitation exercise training

Phosphatidylserine, phosphatidylcholine, and bis(monoacylglycerol)phosphate

downin humans1

1 study
  1. Phosphatidylserine, phosphatidylcholine, and bis(monoacylglycerol)phosphate is associated with total cholesterol in humans (borderline hyperlipidemia).

    “TC and LDL-C were significantly negatively correlated with phosphatidylserine (PS), phosphatidylcholine (PC), and bis(monoacylglycerol)phosphate (BMP).”

    Human trialborderline hyperlipidemiaerythrocyte membrane

    Effects of combined phytosterols and phospholipids on blood lipids and the fluidity and lipid profiles of the erythrocyte membrane in individuals with borderline hyperlipidemia: a double-blinded randomized controlled trial

    Food & function

More on Phosphatidylserine, phosphatidylcholine, and bis(monoacylglycerol)phosphate

All 210

How this record changed

  1. Summary rewritten as its findings changed.

    As it read before

    Lower total cholesterol is linked with higher mortality in peritoneal dialysis patients. Human trials report decreases with whole grains, aerobic exercise and resistance training in untrained older women, but increases with low-carbohydrate and ketogenic diets; resveratrol results point both ways. A behavior-tailored intervention shows no clear effect compared with usual care.

  2. Summary rewritten as its findings changed.

    As it read before

    Human observational studies link total cholesterol to memory function in APOE4 noncarriers and the rate of processing-speed decline in carriers. Trials report decreases with whole grains, caloric restriction and aerobic exercise, increases with ketogenic or low-carbohydrate diets, and no change with a behavior-tailored intervention compared with usual care.

  3. Summary rewritten as its findings changed.

    As it read before

    Human studies associate total cholesterol with brain aging, epigenetic age acceleration and cognition, and with coronary artery disease in adults with metabolic syndrome. Human trials report reductions with berberine and, in older women, resistance training, but increases with ketogenic versus low-fat, moderate-carbohydrate diets and with filtered Arabica–Robusta coffee. A quercetin trial reports no change.

  4. Summary rewritten as its findings changed.

    As it read before

    Human studies associate total cholesterol with dementia in opposing directions, including lower risk in people with chronic kidney disease, and with higher coronary disease risk. A study in people of European ancestry reports no association with cognitive status. Human trials report cholesterol reductions with multidomain lifestyle interventions and a calorie-restricted DASH diet in sedentary older adults with obesity.

  5. Summary rewritten as its findings changed.

    As it read before

    Human trials report lower total cholesterol with whole grains, plant protein, dietary counseling and multidomain lifestyle intervention. A sustainable healthy diet trial reports a reduction in metabolic phenotype 1 but no change in phenotype 3. Human studies associate total cholesterol with higher coronary artery disease risk in adults with metabolic syndrome and higher dementia risk.

Latest

See all 3,299 papers on total cholesterol